In this episode, Howard, Bill and Kristan discuss GBCA Dose Effectiveness.
- Describe how the standard dose of 0.1 mmol/kg was determined
- List the benefits of higher dose
- Define relaxivity
- Compare the relaxivity of the current FDA approved GBCAs
- State the benefit of delaying T1-weighted imaging following GBCA administration
- Describe the benefits of acquiring the T2-FLAIR sequence immediately following GBCA administration
- List the benefits of 3D acquisitions post-GBCA administration
- State desired characteristics of a GBCA
The content of this Contrast Enhanced MRI Program is intended for healthcare professionals who work in the MRI environment. These individuals include MRI Technologists, Imaging Nurses, MRI Researchers, and Others.
This program has been submitted for 1.00 hour of Category A CE credit as designated by the International Society for MR Radiographers & Technologists (ISMRT) RCEEM.
Release Date: 2/15/2023 | Expires: 2/16/2024
Faculty and Planner Disclosures: In accordance with this policy, faculty and planners must disclose any financial relationships with commercial interests germane to program content. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of NWIF to ensure that the COI is resolved in order to ensure the integrity of the CME/CE activity. The planner has nothing to disclose
This MRiCast episode is supported by Bracco Diagnostics Inc. through an unrestricted educational grant.